16:55:34 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2024-09-10 Årsstämma 2025
2024-05-30 Bokslutskommuniké 2024
2024-02-28 Kvartalsrapport 2024-Q3
2023-11-28 Kvartalsrapport 2024-Q2
2023-09-08 Ordinarie utdelning QCORE 0.00 SEK
2023-09-07 Årsstämma 2024
2023-08-30 Kvartalsrapport 2024-Q1
2023-05-30 Bokslutskommuniké 2023
2023-02-28 Kvartalsrapport 2023-Q3
2022-11-28 Kvartalsrapport 2023-Q2
2022-09-08 Ordinarie utdelning QCORE 0.00 SEK
2022-09-07 Årsstämma 2023
2022-08-30 Kvartalsrapport 2023-Q1
2022-06-08 Bokslutskommuniké 2022
2022-02-28 Kvartalsrapport 2022-Q3

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Qlucore är verksamt inom teknikbranschen. Bolaget är specialiserat inom utveckling av 3d-visualisering. Programvaran är egenutvecklad och används huvudsakligen för att identifiera och analysera strukturer och mönster. Mjukvaran gör det möjligt för användaren att utforska och analysera stora datamängder, interaktivt och i realtid med användning av en vanlig dator. Kunderna består av företagskunder verksamma inom forskning och diagnostik. Qlucore grundades 2007 och har sitt huvudkontor i Lund.
2023-02-28 18:30:00

Contract with Notified body – one step closer to approved product

Third quarter, 1 November 2022 - 31 January 2023

· Net sales amounted to SEK 4,289k (5,529k).
· Operating result (EBIT) amounted to SEK -2,884k (327k).
· Net result for the period amounted to SEK -2,899k (410k).
· Earnings per share amounted to SEK -0.72 (0.10). Earnings per share after dilution amounted to SEK -0.72 (0.10).
· Cash flow from operating activities amounted to -3,863 (-526) kSEK.
· During the period we signed a contract with a Notified Body.
· During the period additional research and development grants of SEK 4.7 million have been received for the development of precision medicine solutions for cardiovascular diseases.

First nine months, 1 May 2022 - 31 January 2023

· Net sales amounted to SEK 10,074k (10,525k).
· Operating result (EBIT) amounted to SEK –11,977k (-7,915k).
· Net result for the period amounted to SEK -11,880k (-7,942k).
· Earnings per share amounted to SEK -2.95 (-2.56). Earnings per share after dilution amounted to SEK -2.95 (-2.56).
· Cash flow from operating activities amounted to SEK -9,545k (-5,251k).
· Cash and short-term investments amounted to SEK 75,663k at the closing day.

CEO’s statement
Strategic milestone passed
During the quarter we passed an important milestone by signing a contract with a Notified Body for the certification of Qlucore Diagnostics according to IVDR (CE marking), which will be required for the launch of the product. We are purposefully working further to consolidate our position in the cancer diagnostics segment. Through our method, a faster and simpler analysis of data linked to different forms of cancer is enabled. At the same time, we continue with development and sales in the data analysis segment.
During the quarter we received information that, together with several European research groups, we received development grants from the EU for the development of precision medicine solutions regarding cardiovascular diseases. The project will run for five years and the contribution to Qlucore amounts to approximately SEK 4.7 million. This is the second contribution in a short time in this area.
 Net sales during the third quarter were 22% lower than the corresponding quarter last year. This was in line with expectations as the same quarter last year was 50% higher than a year earlier due to more multiyear deals with larger customers. We will always have differences between quarters due to a combination of the results of new sales and variations in renewal sales.
Overall, net sales during the first nine months of the year amounted to SEK 10,074k compared to SEK 10,525k in the corresponding period last year, which is 4% lower (13% lower if currency effects are considered). The data analysis segment still accounts for most net sales. Investments in precision diagnostics entail higher costs, which negatively affects results, and this is in line with our development plan.

Environmental factors
We still see no direct impact from the ongoing
war in Ukraine, nor do we have customers or
suppliers in Russia.
Global economic trends, such as rising inflation
and the risk of recession, have not affected operations during the period. Historically, our
customers have not been cyclic sensitive, however we continue to monitor developments. Furthermore, we have noted that some companies in the technology sector, just like in biotech, especially in the USA, are carrying out layoffs. We have not yet noticed any direct effect, but it is a sign of increased uncertainty.
 
CE marking
CE marking for Qlucore Diagnostics is extensive work. The contract with a Notified Body is important from several perspectives, partly because Notified Bodies are a scarce resource that is now secured, partly because it requires project maturity on our part to be able to agree on a contract. We are now awaiting feedback on the exact timetables and available resources to be able to communicate the target date for CE marking.

Development
The development work continues to focus on two areas, partly on new software versions for the data analysis segment, and partly on adaptations of the Qlucore Diagnostics platform to match the regulatory requirements. Together with partners we continue to develop models for the diagnosis of lung cancer, breast cancer and bladder cancer, complementing our applications for leukemia (ALL and AML). During the period, we carried out the first demonstration of a preliminary classification model for bladder cancer.